Psyence Biomedical (PBM) Income from Continuing Operations (2023 - 2025)
Psyence Biomedical (PBM) recorded quarterly Income from Continuing Operations of 1504977.0 in Q3 2025, down 230.18% quarter-over-quarter from 1156102.0 in Q3 2024, and down 230.18% on a YoY basis from 1156102.0 in Q3 2024.
Psyence Biomedical (PBM) Income from Continuing Operations (2023 - 2025) Analysis & Trends
Psyence Biomedical's Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 1504977.0 for Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | 727.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.50 Mn |
| Sep 30, 2024 | 1.16 Mn |
| Mar 31, 2023 | -3.23 Mn |